Top ▲

Celiac disease

Disease ID:1031
Name:Celiac disease
Associated with:3 targets
1 immuno-relevant ligand
Database Links
Disease Ontology: DOID:10608

Targets

CIITA
NLRP1
regulator of G-protein signaling 1
References:  1-9

Ligands

Key to terms and symbols Click ligand name to view ligand summary Click column headers to sort
Ligand References Clinical and Disease comments
petesicatib
Immuno Disease Comments: Completed Phase 1 evaluation in celiac patients- see NCT02679014.
Clinical Use: (RO5459072 or RG7625) has completed Phase 2 clinical evaluation in Sjögren's syndrome (NCT02701985) and Phase 1 in celiac disease (NCT02679014), but there are no active clinical trials registered with ClinicalTrials.gov. | View clinical data
Bioactivity Comments: Petesicatib (RO5459072) is selective for cathepsin S compared to other cathepsin isozymes examined [10]. | View biological activity

References

Show »

1. Amundsen SS, Rundberg J, Adamovic S, Gudjónsdóttir AH, Ascher H, Ek J, Nilsson S, Lie BA, Naluai AT, Sollid LM. (2010) Four novel coeliac disease regions replicated in an association study of a Swedish-Norwegian family cohort. Genes Immun., 11 (1): 79-86. [PMID:19693089]

2. Gibbons DL, Abeler-Dörner L, Raine T, Hwang IY, Jandke A, Wencker M, Deban L, Rudd CE, Irving PM, Kehrl JH et al.. (2011) Cutting Edge: Regulator of G protein signaling-1 selectively regulates gut T cell trafficking and colitic potential. J. Immunol., 187 (5): 2067-71. [PMID:21795595]

3. Guo CC, Wang M, Cao FD, Huang WH, Xiao D, Ye XG, Ou ML, Zhang N, Zhang BH, Liu Y et al.. (2016) Meta-Analysis on Associations of RGS1 and IL12A Polymorphisms with Celiac Disease Risk. Int J Mol Sci, 17 (4). [PMID:27043536]

4. Hunt KA, Zhernakova A, Turner G, Heap GA, Franke L, Bruinenberg M, Romanos J, Dinesen LC, Ryan AW, Panesar D et al.. (2008) Newly identified genetic risk variants for celiac disease related to the immune response. Nat. Genet., 40 (4): 395-402. [PMID:18311140]

5. International Multiple Sclerosis Genetics Consortium, Wellcome Trust Case Control Consortium 2, Sawcer S, Hellenthal G, Pirinen M, Spencer CC, Patsopoulos NA, Moutsianas L, Dilthey A, Su Z et al.. (2011) Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature, 476 (7359): 214-9. [PMID:21833088]

6. Izzo V, Pinelli M, Tinto N, Esposito MV, Cola A, Sperandeo MP, Tucci F, Cocozza S, Greco L, Sacchetti L. (2011) Improving the estimation of celiac disease sibling risk by non-HLA genes. PLoS ONE, 6 (11): e26920. [PMID:22087237]

7. Plaza-Izurieta L, Castellanos-Rubio A, Irastorza I, Fernández-Jimenez N, Gutierrez G, CEGEC, Bilbao JR. (2011) Revisiting genome wide association studies (GWAS) in coeliac disease: replication study in Spanish population and expression analysis of candidate genes. J. Med. Genet., 48 (7): 493-6. [PMID:21490378]

8. Romanos J, Barisani D, Trynka G, Zhernakova A, Bardella MT, Wijmenga C. (2009) Six new coeliac disease loci replicated in an Italian population confirm association with coeliac disease. J. Med. Genet., 46 (1): 60-3. [PMID:18805825]

9. Smyth DJ, Plagnol V, Walker NM, Cooper JD, Downes K, Yang JH, Howson JM, Stevens H, McManus R, Wijmenga C et al.. (2008) Shared and distinct genetic variants in type 1 diabetes and celiac disease. N. Engl. J. Med., 359 (26): 2767-77. [PMID:19073967]

10. Tato M, Kumar SV, Liu Y, Mulay SR, Moll S, Popper B, Eberhard JN, Thomasova D, Rufer AC, Gruner S et al.. (2017) Cathepsin S inhibition combines control of systemic and peripheral pathomechanisms of autoimmune tissue injury. Sci Rep, 7 (1): 2775. [PMID:28584258]